# Efficacy and Safety of CKD-828 to Stage 2 Hypertension

> **NCT01634295** · PHASE3 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 103 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** CKD-828 2.5/40mg
- **DRUG:** CKD-828 5/40mg
- **DRUG:** CKD-828 5/80mg
- **DRUG:** S-amlodipine 2.5mg
- **DRUG:** S-amlodipine 5mg

## Key facts

- **NCT ID:** NCT01634295
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2013-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01634295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01634295, "Efficacy and Safety of CKD-828 to Stage 2 Hypertension". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01634295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*